Immunosuppressants Articles & Analysis
62 news found
The threat is heightened where immunosuppressed occupants are present. The threat is further exacerbated where compromised populations spend extended time, such as hospitals, long-term care and skilled nursing ...
Our areas of expertise include new chemical entities (NCEs), carbohydrates, nucleotides, steroids, technical compounds, peptides, immunosuppressants, neurotransmitters, oligonucleotides, polymer mixtures, etc.,” commented the senior scientist of CD Genomics. ...
Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofi’s business footprint, and digital health solutions. 1 Wei Y, Ren X, Galbo PM Jr, et al. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sci Immunol. 2021 Jul 9;6(61):9792. 2 Bhatt RS, Berjis A, Konge JC, et al. ...
ByBayer AG
“The mechanism of action of ATG-037 in inhibiting adenosine-generating CD73 is expected to reverse an immunosuppressed tumor microenvironment, thereby creating potential additive benefit with multiple immuno-oncological approaches. ...
Anti-LILRB2 mAb ES009 has demonstrated superior effects in converting immunosuppressive myeloid cells into pro-inflammation phenotypes in in vitro and ex vivo models. ...
CD73 generates adenosine, which leads to immunosuppression in the tumor microenvironment. ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with ICIs and chemotherapy agents. ...
Title: SIGLEC15 induces monocyte apoptosis and an SIGLEC15 antibody ES012 reverses myeloid cells driven immunosuppression Abstract No.: 1401 Date and time: 11/10/2022, 9:00 am - 9:00 pm ...
Presentation Details Title: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME Abstract Number: 751 Presentation Type: Poster Presentation Onsite Location: Poster Hall Date: November 10, 2022 9 a.m. ...
Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune ...
As part of the RubrYc transaction, the Company now wholly-owns, with no further financial commitments, its lead immune-oncology asset, IBIO-101; an IL-2 sparing anti-CD25 antibody aimed at depleting immunosuppressive regulatory T cells without interfering with T effector cell anti-tumor effects. ...
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. ...
Immunocompromised persons, including those on immunosuppressant therapy, may have a diminished immune response to PreHevbrio. ...
As a myeloid checkpoint inhibitor, IO-108 has demonstrated the ability to relieve immunosuppression in the tumor microenvironment by blocking LILRB2. The combination of IO-108 and anti-PD-1 may enable more patients across multiple solid tumor types to benefit from immune checkpoint inhibitors,” commented by Maggie Gu, China general manager of Immune-Onc. ...
Immunocompromised persons, including those on immunosuppressant therapy, may have a diminished immune response to PreHevbrio. ...
Fosun Pharma has been authorized by Neovii to exclusively sell and develop its immunosuppressant Grafalon ® (anti-human T cell rabbit immunoglobulin injection, hereinafter referred to as the "cooperative product") in China, Hong Kong, Macao and Taiwan. ...
Immunocompromised persons, including those on immunosuppressant therapy, may have a diminished immune response to PreHevbrio. ...
Immunocompromised persons, including those on immunosuppressant therapy, may have a diminished immune response to PreHevbrio. ...
Uses of Proceeds and Planned Milestones Proceeds from the transaction are expected to provide Senti Bio with capital to further develop its gene circuit technologies and therapeutic pipeline, including: Conducting Investigational New Drug- (IND) enabling studies for SENTI-202 and SENTI-301 Building out clinical-scale current good manufacturing practice (cGMP) capabilities and enabling cGMP ...
“We currently manage high-level BK viremia by reducing immunosuppressive therapy, which can help a patient’s immune system clear the virus, but this approach raises the risk that the immune system will attack and reject the graft. ...
ByKalaris
LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. ...